As in mice that received anti–PD-1 monotherapy, JAKi treatment prevented the development of ICI-T1DM in mice treated with combination anti–PD-1 + anti–CTLA-4 (Supplemental Figure 4B). The gene discussed is CTLA4; the disease is type 1 diabetes mellitus.